CD274 and non-small cell lung carcinoma: In another recent study involving 1214 patients with non-small cell lung cancer (NSCLC), the efficacy of avelumab (a human anti-PD-L1 IgG1 antibody) was evaluated in 688 patients, compared with 526 patients receiving platinum-based doublet chemotherapy.